### Sérgio Coxilha

**De:** Marta da Silva Gameiro

Enviado: 17 de junho de 2022 14:11

Para: Comissão 9<sup>a</sup> - CS XV


**Assunto:** documentação Petição contra a vacinação covid em crianças e jovens

Bom dia, peço desculpa pela demora.

Segue neste email todos os artigos nos quais me sustentei para fazer a minha apresentação. Estou em contacto com o Dr Michael Palmer e com o Dr Suckarit caso seja preciso algum tipo de explicação mais específica.

https://odysee.com/@MartaGB:2/MichaelPalmer:6- minha reunião com ele onde explica os slides que apresentei e também imagens com os achados histológicos que foram encontrados em autópsias

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793348- dados sobre danos cerebrais ocorrendo menos de 28 dias após a toma



Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network

Supplement. eTable 1. National and combined rate ratio of selected thromboembolic and thrombocytopenic outcomes in the 28-day period following vaccination compared to the unvaccinated period in a self-controlled case series analysis of the AZD1222 vaccine in Norway, Finland, and Denmark from January 1, 2020, through May 16, 2021 jamanetwork.com

?

https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01831-0- Em conclusão, a vacinação COVID-19 é um importante fator de risco para infecções em pacientes críticos. uso adequado de antibióticos, cessação do tabagismo, controle do estresse e limitação do uso de emulsões lipídicas, incluindo propofol, que pode causar imunossupressão perioperatória. Em conclusão, a vacinação COVID-19 é um importante fator de risco para infecções em pacientes críticos.



# Adverse effects of COVID-19 vaccines and measures to prevent them | Virology Journal | Full Text

Recently, The Lancet published a study on the effectiveness of COVID-19 vaccines and the waning of immunity with time. The study showed that immune function among vaccinated individuals 8 months after the administration of two doses of COVID-19 vaccine was lower than that among the unvaccinated individuals. According to European Medicines Agency recommendations, frequent COVID-19 booster shots ... virologyj.biomedcentral.com

https://jamanetwork.com/journals/jama/fullarticle/2792524- Eficácia decai ao fim de muito pouco tempo não justificando os riscos



Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance | Adolescent Medicine | JAMA | JAMA Network

The graph shows BNT162b2 2-dose adjusted estimated vaccine effectiveness (VE =  $[1 - \text{odds ratio}] \times 100\%$ ) with 95% CI against symptomatic SARS-CoV-2 infection for children aged 5 to 11 years (shown in blue) and adolescents aged 12 to 15 years (shown in orange), from December 26, 2021, to February 21, 2022. jamanetwork.com

?

https://jkms.org/pdf/10.3346/jkms.2022.37.e52- estudo de caso de Mielite transversa associada à vacinação covid

https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-987026- a proteína spike é a principal responsável pela lesão das células do endotélio 8provocando posteriormente coágulos)- estudo em ratos

https://pmj.bmj.com/content/early/2022/01/05/postgradmedj-2021-141022 - síndrome de Ramsay Hunt associado à vacinação



#### Ramsay Hunt syndrome following COVID-19 vaccination

The COVID-19 pandemic has caused profound social and economic upheaval. COVID-19 vaccines promise to prevent infection of the SARS-CoV-2 virus. However, due to their expedited approval, these vaccines need to be vigilantly monitored for their safety. Cases of Bell's palsy have also been reported after COVID-19 vaccine injection. In two phase III trials of COVID-19 vaccines involving around ... pmj.bmj.com

[2]

https://worldcouncilforhealth.org/resources/covid-19-vaccine-pharmacovigilance-report/- relatório independente que recolheu dados existentes nas várias plataformas de farmacovigilância para estabelecer um uma perspectiva da segurança da vacinação (OMS, VAERS, EudraVigilance, UK Yellow Card Scheme)



#### Covid-19 Vaccine Pharmacovigilance Report

Introduction. This report was prepared by the World Council for Health (WCH). The report was prepared to determine whether sufficient pharmacovigilance data exists on WHO VigiAccess, CDC VAERS, EudraVigilance, and UK Yellow Card Scheme to establish a safety signal on Covid-19 vaccines. worldcouncilforhealth.org

?

https://papers.ssrn.com/sol3/papers.cfm?abstract id=4125501- Pré-print da UK Health Security Agency: mais de metade das mortes pediátricas 100 após a infecção por Sars Cov 2 não estavam relacionadas com o Covid. Nas mortes por Covid, 75% tinham condições associadas especialmente "severe neurodisability".

https://www.thelancet.com/journals/lancet/article/PIIS0140-67362200089-7/fulltext- estudo Sueco, eficácia da vacina cai para valores negativos passados 7 meses, o que significa que acaba por contribuir para mais infecções.

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden - The Lancet

We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according to vaccine type. With respect to severe COVID-19, vaccine effectiveness seemed to be better maintained, although some waning became evident after 4 months. The results strengthen the evidence-based rationale for administration of a ... www.thelancet.com

?

https://www.researchgate.net/publication/357442961 Creutzfeldt-Jakob Disease After the COVID-19 Vaccination- Associação entre Creutzfeldt-Jakob e a vacinação



#### Creutzfeldt-Jakob Disease After the COVID-19 Vaccination

Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative condition with a rapid disease course and a mortality rate of 100%. Several forms of the disease have been described, and the most ... www.researchgate.net

?

https://rumble.com/v17p2rk-fda-admits-mrna-vaccines-cause-significantly-elevated-risk-of-myocarditis-w.html-reunião da FDA em que admitem um risco acrescido 2x-24x superior de miocardites entre vacinados (a comparação foi feita entre vacinados há mais e menos tempo, pelo que o número real deve ser maior)



FDA Admits mRNA Vaccines Cause "Significantly Elevated" Risk of Myocarditis w/ "Long-Term Effects"

Source:

https://www.youtube.com/watch?app=desktop&v=DfdMsAqkneErumble.com

2

https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=4072489- "Based on the RCTs... mRNA vaccines had no effect on overall mortality despite protecting against fatal Covid-19."- Isto não faz qualquer sentido. Uma vacina eficaz tem de reduzir a mortalidade.



Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? by Christine Stabell Benn, Frederik Schaltz-Buchholzer, Sebastian Nielsen, Mihai G. Netea, Peter Aaby - SSRN

Abstract. Funding: The work on the non-specific effects of vaccines was supported by private donations from Dr. Allan Schapira. The work on non-specific effects of vaccines has previously been supported by the Danish Council for Development Research, Ministry of Foreign Affairs, Denmark [grant number 104.Dan.8.f.], Novo Nordisk Foundation and European Union FP7 support for OPTIMUNISE (grant ... papers.ssrn.com

?

https://www.youtube.com/watch?v=DfdMsAqkneE- reunião entre a FDA e a Novavax onde tornam a referir a alta eficácia vs correlação negativa com a mortalidade geral



Vaccines and Related Biological Products Advisory Committee - 6/7/2022

Join the U.S. Food and Drug Administration for an upcoming meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss an Emergency Use Authorization request from Novavax for a COVID-19 vaccine for individuals 18 and older. www.youtube.com

## Verified myocarditis and pericarditis in the 0-7-day Risk Interval among 18-39-year-old MALES by product and dose

(compared with outcome events in vaccinated comparators on the same calendar days)

|  | Dose    | Analysis                   |                                     |                                     |                               |                    |   |  |  |
|--|---------|----------------------------|-------------------------------------|-------------------------------------|-------------------------------|--------------------|---|--|--|
| Vaccine  |         | Events in<br>Risk Interval | Events in<br>Comparison<br>Interval | Adjusted<br>Rate Ratio <sup>†</sup> | 95%<br>Confidence<br>Interval | 2-sided<br>P-value | Excess cases in<br>Risk Period<br>per million doses |  |  |
| Either mRNA<br>COVID-19<br>Vaccine**                         | Dose 1  | 11                         | 18                                  | 2.10                                | 0.86 - 4.97                   | 0.101              | 5.1   |  |  |
|  | Dose 2  | 59                         | 11                                  | 14.51                               | 7.54 – 29.88                  | <0.001             | 50.6  |  |  |
|  | Booster | 18                         | 5                                   | 7.53                                | 2.66 - 24.53                  | <0.001             | 29.5  |  |  |
| Pfizer-BioNTech<br>(primary)<br>Pfizer-BioNTech<br>(booster) | Dose 1  | 5                          | 12                                  | 1.91                                | 0.56 - 5.87                   | 0.279              | 3.4   |  |  |
|  | Dose 2  | 32                         | 7                                   | 13.98                               | 6.01 - 36.14                  | <0.001             | 44.1  |  |  |
|  | Booster | 10                         | 2                                   | 13.72                               | 2.86 - 104.20                 | <0.001             | 32.3  |  |  |
| Moderna<br>(primary) -<br>Moderna<br>(booster)               | Dose 1  | 6                          | 6                                   | 2.41                                | 0.63 - 9.24                   | 0.193              | 8.2   |  |  |
|  | Dose 2  | 27                         | 3                                   | 23.46                               | 7.49 – 100.76                 | <0.001             | 62.7  |  |  |
|  | Booster | 5                          | 2                                   | 4.56                                | 0.82 - 36.56                  | 0.085              | 21.5  |  |  |



- Comparison interval is 22-42 days after either dose
- Adjusted for VSD site, 5-year age group, sex, race/ethnicity, and calendar date
  \*\* Individual product events may not sum to "Either mRNA COVID-19 Vaccine" total due to heterologous series and/or noninformative events.

## **Novavaxx Vaccine Efficacy (VE)**

Source: FDA EUA Meeting 6/7/2022

|                             | Event      |         | People     |         |        |
|-----------------------------|------------|---------|------------|---------|--------|
|                             | Vaccinated | Placebo | Vaccinated | Placebo | VE     |
| COVID-19 (18-64)            | 15         | 75      | 15,228     | 7,417   | 90.3%  |
| COVID-19 (65+)              | 2          | 4       | 2,044      | 968     | 76.3%  |
| COVID-19 (All participants) | 17         | 79      | 17,272     | 8,385   | 89.6%  |
| DEATH (Pre-Crossover)       | 11         | 5       | 19,735     | 9,847   | -9.8%  |
| DEATH (Post-Crossover)      | 6          | 10      | 6,416      | 15,298  | -43.1% |
| DEATH                       | 17         | 15      | 26,151     | 25,145  | -9.0%  |

Sources:

https://www.youtube.com/watch?v=DfdMsAqkneE

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0041785


Slide apresentado na reunião: elevada eficácia mas correlação negativa com mortalidade

<u>https://globalcovidsummit.org/news/global-covid-summit-pediatric-declaration</u>- declaração de pediatras americanos contra a vacinação de crianças

The Centers for Disease Control and Prevention notes that even though the absolute risk for myopericarditis following mRNA COVID-19 vaccine is small, the relative risk is greater for particular groups, including male patients aged 12-39 years. Some studies have suggested that increasing the interval between the first and second dose may reduce the incidence of myopericarditis in this population.


These data led to an extension in the Centers for Disease Control and Prevention—recommended dosing interval between dose 1 and dose 2 to 8 weeks. Further follow-up assessment and larger multicenter studies are needed to determine the ultimate clinical significance of persistent cardiac MRI abnormalities in patients with post—COVID-19 vaccine myopericarditis. <a href="https://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext">https://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext</a>

https://onlinelibrary.wiley.com/doi/10.1111/apa.16430- artigo que resume muito bem o risco\benefício da vacinação em crianças



The benefits of COVID-19 vaccination programmes for children may not outweigh the risks - Abecasis - - Acta Paediatrica - Wiley Online Library This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. onlinelibrary.wiley.com

https://www.nature.com/articles/s41598-022-10928-z




Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave | Scientific Reports - Nature

Cardiovascular adverse conditions are caused by coronavirus disease 2019 (COVID-19) infections and reported as side-effects of the COVID-19 vaccines. Enriching current vaccine safety surveillance ...

www.nature.com

## https://thorax.bmj.com/content/77/1/102



#### COVID-19 vaccine-related interstitial lung disease: a case study

Herd immunity through extensive and rapid vaccination rather than natural immunity acquired by infection is necessary to control a global pandemic like COVID-19. The development of COVID-19 vaccines has been accelerated through government funding and the collaborative efforts of the medical–scientific institutions and the pharmaceutical industry.1 2 In South Korea, the ChAdOx1 nCoV-19 ...

thorax.bmj.com

https://pubmed.ncbi.nlm.nih.gov/35648413/- Não foi encontrada diferença em termos de protecção aumentada para o bebé, ao vacinar grávidas



# Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants


The results of this Norwegian population-based cohort study suggested a lower risk of a positive test for SARS-CoV-2 during the first 4 months of life among infants born to mothers who were vaccinated during pregnancy. Maternal COVID-19 vaccination may provide passive protection to young infants, fo ... pubmed.ncbi.nlm.nih.gov

<u>https://www.nature.com/articles/s41379-022-01069-9</u>- anticorpo foi associado com um aumento forte de disseminação viral o que suporta a hipótese que o sistema imunitário deicou de conseguir fazer uma resposta primária.

https://pubmed.ncbi.nlm.nih.gov/35456309/- Não foi encontrado um aumento de incidência de miocardites pós-infecção em não vacinados

https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/covidwho-1512739- estudo da Arabia Saudita publicado na revista Vaccines sobre os efeitos secundários encontrados em jovens dos 12-18 anos.

https://jessicar.substack.com/p/stillbirths-miscarriages-and-abortions- este artigo deve ser analisado com reservas porque não está publicado. É um estudo independente do Dr Josh Guetzkow, criminologista na Universidade Hebraica de Jerusalém e reflete apenas os dados de dois Hospitais.



Title: Stillbirths, Miscarriages and Abortions in Vaccinated vs. Unvaccinated Women

Evidence from an Israeli hospital by Josh Guetzkow jessicar.substack.com

### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021033/-



#### SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis

Autoimmune hepatitis episodes have been described following SARS-CoV-2 infection and vaccination but their pathophysiology remains unclear. Herein, we report the case of a 52-year-old male, presenting with bimodal episodes of acute hepatitis, each occurring ... www.ncbi.nlm.nih.gov


https://pubmed.ncbi.nlm.nih.gov/34888935/- aumento de incidência de úlceras vulvares aós a vacinação aos 12 anos



#### Vulvar aphthous ulcer after COVID-19 vaccination - PubMed

Vulvar aphthous ulcer, also known as acute genital ulceration or Lipschutz ulcers, is an uncommon, non-sexually acquired condition characterized by sudden onset ulcerations of the vulva in young girls and women. It is thought to represent an immunologic reaction to an infection or other source of in ... pubmed.ncbi.nlm.nih.gov

https://www.nature.com/articles/s41591-022-01840-0- vacinação com pouca eficácia no Long Covid




#### Long COVID after breakthrough SARS-CoV-2 infection

The post-acute sequelae of SARS-CoV-2 infection—also referred to as Long COVID—have been characterized 1.Increasingly, vaccinated individuals are being diagnosed with COVID-19 as a result of ... www.nature.com

Vou enviar também o relatória que a Pfizer entregou à FDA para justificar a vacinação em crianças, salientando que a eficácia foi calculada em apenas 10 casos e SÓ após a 3ª dose! Passam 200 dias desde a primeira dose até conseguirem um valor positivo. A dosagem da Moderna é também 8x superior à da Pfizer.

#### https://www.fda.gov/media/159195/download



Por último gostaria de salientar que não basta inventar uma tecnologia e charmar-lhe de vacina para automaticamente ser "segura e eficaz". Os ensaios clínicos demoram entre 10 a 15 anos por alguma razão e por muito dinheiro que se meta há coisas que são impossiveis de acelerar.

Há vários indícios que houve fraude nos ensaios clínicos além da própria OMS desencorajar a atribuição de causalidade de morte às vacinas durante os ensaios (tenho o relatório em questão: https://davidhealy.org/wp-content/uploads/2022/06/WHO-AEFI.pdf).

https://jackanapes.substack.com/p/is-subject-12312982-the-key-to-proving



## Is Subject #12312982 the Key to Proving Pfizer Vaccine Trial Fraud?

On Sept. 14, he was discharged. The doctor wrote in his chart that he had suffered an adverse reaction to the vaccine. Augusto was told by hospital staff they there had been a huge influx of people from the clinical trial coming to the hospital (there were 2,981 subjects enrolled in the trial before Augusto), so his experience was not new to them.

jackanapes.substack.com

Obrigada pela atenção, Marta Gameiro